Neika Vendetti, United States of America

Merck & Co Inc. Pharmacoepidemiology

Poster Author Of 2 e-Posters

Online Abstracts Clinical Sciences - Disease Burden in Infants, Children/Youth, and Adults B2 Disease Burden in Infants, Children/Youth, and Adults
Online Abstracts Clinical Sciences - Disease Burden in Infants, Children/Youth, and Adults B2 Disease Burden in Infants, Children/Youth, and Adults

Presenter of 1 Presentation

PNEUMOCOCCAL SEROTYPE DISTRIBUTION: RECENT DATA IN ADULT POPULATIONS AROUND THE WORLD, 2017-2019 (ID 843)

Abstract

Background

Pneumococcal disease remains a global health problem despite availability of vaccines (pneumococcal polysaccharide (PPV23) and pneumococcal conjugate vaccines (PCV)). Non-vaccine serotypes have emerged. As part of ongoing surveillance to monitor vaccine impact and identify newly emerging serotypes, literature was reviewed.

Methods

Medline, EMBASE, and Cochrane databases were searched from February 2017 to May 2019. Serotype distribution data for adults ≥18 years were extracted and summarized.

Results

Serotype data were available in 22 articles covering 2012 onwards with the majority from areas where PCV was part of a pediatric immunization program. Articles covered invasive pneumococcal disease (IPD) (n=14), non-IPD (n=4), carriage (n=3), and IPD and non-IPD combined (n=1). Serotypes included in PCV13, PPV23, or in no vaccine accounted for 32.8%, 42.0% and 25.3% of serotyped isolates, respectively. The most common PCV13 and PPV23 serotypes were 3, 19A & 7F and 3, 8 & 22F, respectively. The most common non-vaccine serotypes were 15A, 6C and 23A. A similar distribution was seen among adults ≥65 years. PCV13 serotypes were more prevalent in non-IPD and carriage.

Conclusions

After pediatric PCV adoption in various countries, several vaccine and non-vaccine serotypes remain responsible for a significant burden of disease among adults, informing the needs for future adult vaccines.

Hide

Author Of 2 Presentations

PNEUMOCOCCAL SEROTYPE DISTRIBUTION: RECENT DATA IN PEDIATRIC POPULATIONS AROUND THE WORLD, 2017-2019 (ID 342)

Abstract

Background

Despite availability of conjugate (PCV) and pneumococcal polysaccharide vaccines (PPV23), pneumococcal disease remains a global health problem. Emergence of non-vaccine serotypes continues to be a threat. As part of an ongoing program, literature was reviewed to inform recent changes in serotype distribution.

Methods

Medline, EMBASE and Cochrane databases were searched from February 2017–May 2019. Serotype distribution data for children ≤5 years were extracted and summarized.

Results

Serotype data were available in 51 articles covering varying periods from 2012 onwards, including 39 publications from areas/periods where pediatric PCV was part of immunization programs. Most (30) papers covered nasopharyngeal carriage, 21 covered invasive pneumococcal disease (IPD), one each covered acute otitis media and non-IPD, and three pooled IPD and non-IPD. Overall, PCV13, PPV23-specific and non-vaccine serotypes accounted for 39.7%, 27.8% and 32.4% of serotyped isolates, respectively. Six of the 10 most prevalent serotypes were PCV13-specific. Among PPV23 serotypes, 15B/C, 11A and 10A ranked in the top 10. Global prevalence of serotypes 22F and 33F was 0.7% and 0.8%, respectively. The most prevalent non-vaccine serotypes were 23B, 15A/F, 23A, 21 and 16F.

Conclusions

PCV serotypes remain responsible for a significant burden of pneumococcal disease in children, even in countries using PCV.

Hide

PNEUMOCOCCAL SEROTYPE DISTRIBUTION: RECENT DATA IN ADULT POPULATIONS AROUND THE WORLD, 2017-2019 (ID 843)

Abstract

Background

Pneumococcal disease remains a global health problem despite availability of vaccines (pneumococcal polysaccharide (PPV23) and pneumococcal conjugate vaccines (PCV)). Non-vaccine serotypes have emerged. As part of ongoing surveillance to monitor vaccine impact and identify newly emerging serotypes, literature was reviewed.

Methods

Medline, EMBASE, and Cochrane databases were searched from February 2017 to May 2019. Serotype distribution data for adults ≥18 years were extracted and summarized.

Results

Serotype data were available in 22 articles covering 2012 onwards with the majority from areas where PCV was part of a pediatric immunization program. Articles covered invasive pneumococcal disease (IPD) (n=14), non-IPD (n=4), carriage (n=3), and IPD and non-IPD combined (n=1). Serotypes included in PCV13, PPV23, or in no vaccine accounted for 32.8%, 42.0% and 25.3% of serotyped isolates, respectively. The most common PCV13 and PPV23 serotypes were 3, 19A & 7F and 3, 8 & 22F, respectively. The most common non-vaccine serotypes were 15A, 6C and 23A. A similar distribution was seen among adults ≥65 years. PCV13 serotypes were more prevalent in non-IPD and carriage.

Conclusions

After pediatric PCV adoption in various countries, several vaccine and non-vaccine serotypes remain responsible for a significant burden of disease among adults, informing the needs for future adult vaccines.

Hide